HF21 / 21 episodes / 21 minutes: CHFS Perspective and Case-Based Approach on the 2021 CHFS / CCS HF Guidelines

06/09/2021 11/25/2021

About

Canadian experts will share their practical tips around the implementation of CCS/CHFS guidelines into the management of your patients with heart failure.

Learning Objectives

1. Apply recommendations from the 2021 CCS/CHFS Guidelines Update into clinical practice
2. Assess the importance of implementing 4 key therapeutic drug classes as standard therapy for most patients with HFrEF
3. Evaluate which patients will require additional key therapies and non-pharmacological interventions based on individual clinical characteristics

Speakers

Others


  • Grace Chua

    MD, FRCPC, FACC

    Dr. Grace Chua is a staff cardiologist at Mackenzie Health in Richmond Hill/Vaughan, Ontario. She obtained her medical degree from the University of Toronto, followed by internal medicine and cardiology training at University Health Network in Toronto, including a fellowship in Clinical Epidemiology and Adult Echocardiography. During her cardiology training, she did research combining clinical epidemiology and cardiology leading to a publication in the New England Journal of Medicine that has been instrumental in initiating the declaration of conflict of interest in medicine that we see today. She is a Fellow of the Royal College of Physicians and Surgeons in Cardiology as well as a Fellow of the American College of Cardiology. As a community cardiologist, she was the Chief of the Division of Cardiology at Mackenzie Health from September 2003 to March 2017 and was the initiating force in the development of the hospital’s rapid access chest pain clinic and heart function service. Currently, her interests lie in clinical education and knowledge translation, particularly in the field of heart failure, as well as prevention of cardiovascular disease.
  • Graham Wong

    MD, MPH, FRCPC, FACC FCCS, FAHA

  • Jonathan Howlett

    MD, FRCPC, FCCS, FACC, FHFSA (HON)

  • Lisa Mielniczuk

    MD, FRCPC

    Dr. Mielniczuk completed her medical degree at McMaster University and subsequently went on to complete a residency in Internal Medicine from Queen's University and a Cardiology Fellowship at the University of Ottawa Heart Institute. She also completed a fellowship in advanced heart failure/cardiac transplantation at the Brigham and Women's Hospital in Boston - where she also concurrently completed a Master's Degree in Clinical Science and Epidemiology at the Harvard School of Public Health. Dr. Mielniczuk is currently an Professor of Medicine at the University of Ottawa and the Director of the Advanced Heart Diseases Program at the Ottawa Heart Institute. She is also cross-appointed to the Department of Cellular and Molecular Medicine. Her commitment to leadership and program development is evident in her multiple accomplishments at the Heart Institute, including being the co-Founder and Director of the Pulmonary Hypertension Program, developing a Rapid Intervention Clinic for HF patients, and a Regional HF program for the Ottawa/Champlain region. She is a translational scientist and currently holds a University of Ottawa Chair in Heart Function Research, has more than 100 peer reviewed papers, and has built a multi-disciplinary right heart failure research program at the University of Ottawa. Provincially and Nationally, Dr. Mielniczuk is an active leader for the HF and Pulmonary Hypertension community and serves on the Pulmonary Hypertension Association of Canada Board of Directors. Dr. Mielniczuk is a member of the CorHealth Ontario Senior Leadership Council for Cardiac Disease, as well as an expert panel member for CADTH and Health Quality Ontario. She has been a Canadian Cardiovascular Society Council member since 2015 and is currently serving as the Secretary and treasurer for the Executive. In 2019 Dr. Mielniczuk was appointed Vice-Chair of Patient Safety and Clinical Care for the Department of Medicine at the University of Ottawa.
  • Ryan Davey

    MD, FRCPC, FACC

    Originally hailing from Niagara Falls, Ontario, Dr. Davey completed his undergraduate work at the University of Toronto, before moving on to medical school in Dublin, at the Royal College of Surgeons in Ireland.  He became the first Irish medical graduate to directly take up residency after graduation at Western University in Internal Medicine (2008-2011).  He continued on with subspecialty training in Cardiology (2011-2014), also in London, Ontario.

    After completion of his residency training, Dr. Davey moved to Pittsburgh, Pennsylvania, where he was accepted into a two-year Advanced Heart Failure, Transplant, Left Ventricular Assist Device (LVAD) and Pulmonary Hypertension (PH) fellowship, under Drs. Raymond Benza and Srinivas Murali, at the Allegheny General Hospital.  While there he was involved in, and subsequently presented and published, a number of research projects, mainly centering around therapy exchange for PH.  Although he is involved with a number of different cardiac societies, most of his interest and focus is in the International Society for Heart and Lung Transplantation (ISHLT).

    Dr. Davey is a fellow of the Royal College of Physicians and Surgeons of Canada (Internal Medicine, Cardiology) and the American College of Cardiology.  He is American Board Certified in Internal Medicine, Cardiology and Advanced Heart Failure and Transplantation.

    Dr. Davey joined the Division of Cardiology Heart Failure Service as an Assistant Professor in September 2016 and is the medical lead for the LVAD Program.

  • Sabe De

    MD, FRCPC, FASE

  • Shelley Zieroth

    MD, FCCS, FHFSA (HON), FESC, FACC, FHFA, FRCPC

Sponsors

  • Novartis

  • Boehringer Ingelheim (Canada) Ltd. & Eli Lilly and Company

    PLATINUM